Predictors of Survival in Myelodysplastic Patients with Cardiovascular Disease

Conclusion: CV disease is well accepted predictor of poor survival among MDS pt. However, to our knowledge, previous studies examining predictors for outcome in LR-MDS pt diagnosed with CV has not been reported before. MCV is known erythroid parameter frequently abnormal in pt with MDS. Strong correlation between TET2, deregulated IL-1 beta and macrocytosis has been recently uncovered. In our studied population, median MCV specifically discriminated different survival in LR-MDS pt diagnosed with CV disease. Notably, Hb, RDW, platelet count, ferritin and WHO classification reproduced "unique" survival among LR-MDS pt with and without CV disease. Large studies are needed. However, this report emphasizes the need for differential management in LR-MDS CV (pos) vs CV (neg) pt.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Rivero, G. A., Schroeder, V., Carias, S., Talukder, R., Alcedo, P. E., Frolov, A. Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Poster III Source Type: research